2839. Efficacy, Pharmacokinetics (PK), and Safety Profile of Suvratoxumab (MEDI4893), a Staphylococcus aureus Alpha Toxin (AT)-Neutralizing Human Monoclonal Antibody in Mechanically Ventilated Patients in Intensive Care Units; Results of the Phase 2 SAATELLITE Study Conducted by the Public-Private COMBACTE Consortium

BACKGROUND: Staphylococcus aureus (SA) pneumonia imposes significant morbidity and mortality in mechanically ventilated, intensive care unit (MV ICU) patients despite best clinical care. We assessed efficacy, PK, AT-neutralizing antibodies (AT NAbs), and safety of suvratoxumab (suvra) in MV ICU subj...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Francois, Bruno, Sánchez Garcia, Miguel, Eggimann, Philippe, Dequin, Pierre-Francois, Laterre, Pierre-François, Huberlant, Vincent, Viña Soria, Lucia, Boulain, Thierry, Bretonnière, Cédric, Pugin, Jerome, Trenado Álvarez, José, Catalina Hernandez Padilla, Ana, Coenjaerts, Frank, Ali, Omar, Shoemaker, Kathryn, Ruzin, Alexey, Pierre, Vadryn, Wu, Yuling, Colbert, Susan, McCarthy, Michael, Dubovsky, Filip, S. Jafri, Hasan
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809370/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.144
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados